Record mula sa primary source
Decision-gradeTopline na resulta
Compass nag-ulat ng positibong Phase 2/3 topline para sa tovecimig sa BTC
COMPANION-002 nakamit ang pangunahing ORR endpoint (17.1% vs 5.3%, p=0.031) at nagpakita ng istatistikal na makabuluhang benepisyo sa PFS (4.7 vs 2.6 buwan, HR=0.44). Plano ng kumpanya na makipagkita sa FDA sa mga darating na buwan upang talakayin ang mga datos na ito bago ang nakaplanong BLA submission.
Mahahalagang fact
- Na-file
- Abr 27, 2026, 11:30 AM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
CMPXCompass Therapeutics- Asset
- tovecimig
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- OS
- 8.9 vs 9.4 buwan (HR=1.05, p=0.78)
- ORR
- 17.1% kumpara sa 5.3% (p=0.031)
- PFS
- 4.7 vs 2.6 buwan (HR=0.44, p<0.0001)
- Naitala
- 168
- Paglipat ng grupo (crossover)
- 54%
Sipi mula sa source
Form 8-K False 0001738021 0001738021 2026-04-27 2026-04-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 _______________________________ Compass Therapeutics, Inc. (Exact name of registrant as specified in its charter) _______________________________ Delaware 001-39696 82-4876496 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 80 Guest Street, Suite 601 Boston , Massachusetts 02135 (Address of Principal Executive Offices) (Zip Code) ( 617 ) 500-8099 (Registrant'